Chemomab Therapeutics Ltd. SEC filings CMMB
Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| EFFECT | Filing | Oct 30, 2026 | — |
| DEFM14A | Filing | Oct 30, 2026 | — |
| S-4/A | Filing | Oct 29, 2026 | — |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| S-4/A | Filing | Oct 19, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| S-4 | Registration for a merger or exchange | Sep 25, 2026 | — |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Jun 30, 2026 |
| DRS | Filing | Aug 12, 2026 | — |
| 6-K | Current report (foreign issuer) | Jul 8, 2026 | Jul 8, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
| 6-K | Current report (foreign issuer) | May 14, 2026 | May 14, 2026 |
| 6-K | Current report (foreign issuer) | May 6, 2026 | May 6, 2026 |
| 6-K | Current report (foreign issuer) | Apr 28, 2026 | Apr 28, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 23, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 20, 2026 | Mar 20, 2026 |
| 6-K | Current report (foreign issuer) | Mar 19, 2026 | Mar 19, 2026 |
| 6-K | Current report (foreign issuer) | Nov 21, 2025 | Nov 21, 2025 |
| 6-K | Current report (foreign issuer) | Aug 22, 2025 | Aug 22, 2025 |
| 6-K | Current report (foreign issuer) | Aug 14, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Jul 25, 2025 | Jul 25, 2025 |
| 424B5 | Prospectus supplement | Jul 25, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 1, 2025 | Jul 1, 2025 |
| 6-K | Current report (foreign issuer) | May 27, 2025 | May 27, 2025 |
| 6-K | Current report (foreign issuer) | May 15, 2025 | May 15, 2025 |
| 6-K | Current report (foreign issuer) | Apr 15, 2025 | Apr 15, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 4, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 27, 2025 | Mar 27, 2025 |
| 6-K | Current report (foreign issuer) | Mar 20, 2025 | Mar 20, 2025 |
| 6-K | Current report (foreign issuer) | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Current report (foreign issuer) | Feb 19, 2025 | Feb 19, 2025 |
| EFFECT | Filing | Dec 10, 2024 | — |
| POS AM | Filing | Dec 2, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 18, 2024 |
| 424B5 | Prospectus supplement | Nov 15, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Nov 14, 2024 |
| 6-K | Current report (foreign issuer) | Oct 11, 2024 | Oct 11, 2024 |
| 424B3 | Prospectus | Sep 9, 2024 | — |
| EFFECT | Filing | Sep 6, 2024 | — |
| CORRESP | Letter to the SEC | Sep 4, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 23, 2024 | — |
| 6-K | Current report (foreign issuer) | Aug 21, 2024 | Jun 30, 2024 |
| D | Filing | Aug 9, 2024 | — |
| 6-K | Current report (foreign issuer) | Jul 25, 2024 | Jul 25, 2024 |
| 6-K | Current report (foreign issuer) | Jun 12, 2024 | Jun 12, 2024 |
| 6-K | Current report (foreign issuer) | May 9, 2024 | May 9, 2024 |
| 6-K | Current report (foreign issuer) | May 8, 2024 | May 8, 2024 |
| 6-K | Current report (foreign issuer) | May 3, 2024 | May 3, 2024 |
| 20-F | Annual report (foreign issuer) | Mar 28, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Mar 7, 2024 | Mar 7, 2024 |
| 6-K | Current report (foreign issuer) | Jan 3, 2024 | Jan 3, 2024 |
| 6-K | Current report (foreign issuer) | Nov 9, 2023 | Nov 9, 2023 |
| EFFECT | Filing | Nov 3, 2023 | — |
| CORRESP | Letter to the SEC | Nov 1, 2023 | — |
| F-3/A | Filing | Oct 30, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 16, 2023 | — |
| 6-K | Current report (foreign issuer) | Aug 14, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Aug 8, 2023 | Aug 8, 2023 |
| 6-K | Current report (foreign issuer) | Jul 3, 2023 | Jul 3, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 5, 2023 | Jun 1, 2023 |
| RW | Filing | Jun 2, 2023 | — |
| S-1/A | Amended registration statement | May 19, 2023 | — |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| S-1/A | Amended registration statement | Mar 22, 2023 | — |
| S-1/A | Amended registration statement | Mar 21, 2023 | — |
| ARS | Annual report to shareholders | Mar 21, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| S-1/A | Amended registration statement | Feb 22, 2023 | — |
| 8-K |
Current report
Other events
|
Feb 21, 2023 | Feb 21, 2023 |
| S-1/A | Amended registration statement | Feb 21, 2023 | — |
| 8-K |
Current report
Results of operations
|
Feb 21, 2023 | Dec 31, 2022 |
| S-1 | Registration statement | Jan 13, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 11, 2023 | Jan 11, 2023 |
| 8-K |
Current report
Other events
|
Jan 3, 2023 | Jan 3, 2023 |
| 8-K/A | Amended current report | Nov 29, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Other events
|
Nov 16, 2022 | Nov 16, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 14, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| S-8 | Employee stock plan registration | Aug 15, 2022 | — |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2022 | Aug 12, 2022 |
| 8-K | Current report | Jun 21, 2022 | Jun 21, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2022 | Jun 1, 2022 |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| DEF 14A | Proxy statement | Apr 28, 2022 | Apr 28, 2022 |
| 424B5 | Prospectus supplement | Apr 25, 2022 | — |
| 10-K | Annual report | Mar 30, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2022 | Mar 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Feb 11, 2022 | Feb 11, 2022 |
| DEF 14A | Proxy statement | Jan 5, 2022 | Jan 5, 2022 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2021 | Dec 23, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 16, 2021 | Dec 16, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 3, 2021 | Dec 3, 2021 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Nov 12, 2021 | Nov 12, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 8, 2021 | Nov 8, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2021 | Nov 3, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Oct 26, 2021 | Oct 26, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 25, 2021 | Oct 25, 2021 |
| DEF 14A | Proxy statement | Sep 17, 2021 | Sep 17, 2021 |
| S-8 | Employee stock plan registration | Sep 13, 2021 | — |
| PRE 14A | Preliminary proxy statement | Sep 3, 2021 | Sep 3, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 2, 2021 | Sep 2, 2021 |
| 10-Q | Quarterly report | Aug 13, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2021 | Aug 13, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jul 22, 2021 | Jul 22, 2021 |
| DEF 14A | Proxy statement | Jun 14, 2021 | Jun 14, 2021 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2021 | Jun 1, 2021 |
| EFFECT | Filing | May 17, 2021 | — |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| CORRESP | Letter to the SEC | May 12, 2021 | — |
| UPLOAD | Letter from the SEC | May 5, 2021 | — |
| S-3 | Shelf registration | Apr 30, 2021 | — |
| 424B3 | Prospectus | Apr 29, 2021 | — |
| EFFECT | Filing | Apr 28, 2021 | — |
| CORRESP | Letter to the SEC | Apr 26, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2021 | — |
| S-3 | Shelf registration | Apr 15, 2021 | — |
| 8-K/A | Amended current report | Apr 14, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Other events
|
Apr 5, 2021 | Apr 5, 2021 |
| D | Filing | Mar 30, 2021 | — |
| 8-K/A | Amended current report | Mar 19, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Mar 17, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Other events
|
Mar 10, 2021 | Mar 9, 2021 |
| 425 | Form 8-k | Mar 10, 2021 | — |
| 10-K | Annual report | Mar 9, 2021 | Dec 31, 2020 |
| 425 | Filing | Mar 9, 2021 | — |
| 424B3 | Prospectus | Feb 12, 2021 | — |
| EFFECT | Filing | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| S-4/A | Filing | Feb 10, 2021 | — |
| 8-K |
Current report
Other events
|
Feb 8, 2021 | Feb 8, 2021 |
| 425 | Form 8-k | Feb 8, 2021 | — |
| 425 | Filing | Feb 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2021 | — |
| S-4 | Registration for a merger or exchange | Jan 13, 2021 | — |
| 425 | Filing | Jan 11, 2021 | — |
| 425 | Filing | Jan 5, 2021 | — |
| 8-K |
Current report
Material agreement, Other events
|
Dec 15, 2020 | Dec 14, 2020 |
| DEFA14A | Additional proxy material | Dec 15, 2020 | — |
| 10-Q | Quarterly report | Nov 16, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Officer or director change
|
Oct 20, 2020 | Oct 20, 2020 |
| 10-Q | Quarterly report | Aug 14, 2020 | Jun 30, 2020 |
| 8-K |
Current report
Officer or director change
|
Jul 15, 2020 | Jul 15, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 9, 2020 | Jul 9, 2020 |
| 8-K |
Current report
Officer or director change
|
May 21, 2020 | May 21, 2020 |
| 10-Q | Quarterly report | May 7, 2020 | Mar 31, 2020 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 6, 2020 | May 5, 2020 |
| 8-K |
Current report
Shareholder vote results
|
Apr 24, 2020 | Apr 24, 2020 |
| DEFA14A | Additional proxy material | Apr 17, 2020 | — |
| 8-K |
Current report
Listing notice
|
Apr 15, 2020 | Apr 15, 2020 |
| UPLOAD | Letter from the SEC | Apr 7, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2020 | — |
| DEF 14A | Proxy statement | Apr 6, 2020 | Apr 23, 2020 |
| CORRESP | Letter to the SEC | Apr 6, 2020 | — |
| PRE 14A | Preliminary proxy statement | Mar 30, 2020 | Apr 23, 2020 |
| S-8 | Employee stock plan registration | Mar 17, 2020 | — |
| 10-K | Annual report | Mar 17, 2020 | Dec 31, 2019 |
| 8-K |
Current report
Other events
|
Mar 16, 2020 | Mar 16, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 10, 2020 | Feb 10, 2020 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Feb 4, 2020 | Feb 3, 2020 |
| 8-K |
Current report
Other events
|
Jan 31, 2020 | Jan 31, 2020 |
| 8-K |
Current report
Other events
|
Jan 10, 2020 | Jan 9, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 2, 2020 | Jan 2, 2020 |
| 6-K | Current report (foreign issuer) | Nov 21, 2019 | Nov 21, 2019 |
| 6-K | Current report (foreign issuer) | Nov 15, 2019 | Nov 15, 2019 |
| 6-K | Current report (foreign issuer) | Nov 12, 2019 | Nov 12, 2019 |
| 6-K | Current report (foreign issuer) | Oct 28, 2019 | Oct 28, 2019 |
| 6-K | Current report (foreign issuer) | Sep 23, 2019 | Sep 23, 2019 |
| 6-K | Current report (foreign issuer) | Aug 13, 2019 | Aug 13, 2019 |
| 6-K | Current report (foreign issuer) | Aug 6, 2019 | Aug 5, 2019 |
| S-8 | Employee stock plan registration | Jul 22, 2019 | — |
| 6-K | Current report (foreign issuer) | Jul 8, 2019 | Jul 8, 2019 |
| 6-K | Current report (foreign issuer) | Jun 18, 2019 | Jun 18, 2019 |
| 6-K | Current report (foreign issuer) | May 28, 2019 | May 28, 2019 |
| 6-K | Current report (foreign issuer) | May 22, 2019 | May 22, 2019 |
| 20-F/A | Amended annual report (foreign issuer) | Apr 24, 2019 | Dec 31, 2018 |
| 20-F | Annual report (foreign issuer) | Mar 25, 2019 | Dec 31, 2018 |
| 6-K | Current report (foreign issuer) | Mar 14, 2019 | Mar 14, 2019 |
| 6-K | Current report (foreign issuer) | Mar 12, 2019 | Mar 12, 2019 |
| 6-K | Current report (foreign issuer) | Feb 14, 2019 | Feb 14, 2019 |
| 424B4 | Prospectus | Feb 13, 2019 | — |
| 6-K | Current report (foreign issuer) | Feb 12, 2019 | Feb 12, 2019 |
| CT ORDER | Filing | Feb 12, 2019 | — |
| EFFECT | Filing | Feb 11, 2019 | — |
| CERT | Filing | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| F-1/A | Amendment no. 4 to form f-1 | Feb 11, 2019 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534248
- Former names
- Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.